Skip to main content
  1. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
  2. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
  3. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
  4. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
  5. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
  6. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
  7. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
  8. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
  9. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Optimizing tissue tropism, transduction efficiency, and cell-type specificity to lower dosing requir ...
  10. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
  11. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
  12. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
  13. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
  14. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Commercial Lessons from the Front Line: Real-world insights from autologous therapy launches to refi ...
  15. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Key differences in process design, scalability, and consistency between T cell and NK cell platforms ...
  16. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Exploring lessons from OmnImmune®’s transition from fresh to cryopreserved gamma-delta T cells in re ...
  17. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Assay design must reflect γδ T cell-specific mechanisms of action (e.g., cytotoxicity, cytokine rele ...
  18. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Afternoon Refreshments
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Morning Refreshments
  19. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Engineering capsids with enhanced tissue specificity, immune evasion, and payload capacity. Explorin ...
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Evening Drinks Reception
  20. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
  21. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Networking Lunch
  22. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
  23. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Streamlining upstream and downstream workflows to support consistent and scalable autologous product ...
  24. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Proprietary tools enhancing potency, precision, and control in autologous cell therapies. Manufactur ...
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Registration